Pivotal Points in Pediatric Atopic Dermatitis: What You Probably Missed But Shouldn’t Have


This activity is provided by Integrity Continuing Education, Inc.


This activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals.


2022 has been a banner year for patients with pediatric atopic dermatitis (AD) as well as for their parents, families, and healthcare providers. The biologic dupilumab was approved for moderate to severe AD for ages 6 months to 5 years. Adolescents with AD also got new treatment options with approvals of oral systemic and topical JAK inhibitors, upadacitinib and ruxolitinib, respectively. There are also biologics and JAK inhibitors that are now in phase 3 clinical trials for children and adolescents with AD.

Join pediatric AD expert Dr. Peter Lio as he discusses pivotal trials from 2022 to highlight the new and emerging treatments for children and adolescents with AD.


Peter Lio, MD
Clinical Assistant Professor
Department of Dermatology & Pediatrics
Northwestern University
Partner, Medical Dermatology Associates
Chicago, Illinois

Release date: December 14, 2022
Expiration date: December 14, 2023
Estimated time to complete activity: 60 minutes

This educational activity has been designed to meet the needs of pediatric dermatologists, dermatologists, pediatricians, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage pediatric patients with AD.


Upon completion of this educational activity, participants should be able to:

  • Incorporate new biologic and small-molecule treatments for appropriately selected children and adolescents with AD that have not responded adequately to other medications
  • Review clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD

There are no fees for participating and receiving CME credit for this activity. During the period of December 14, 2022 through December 14, 2023 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Peter Lio, MD
Speaker: AbbVie, Eli Lilly, Galderma, Incyte, Leo Pharma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme
Advisory Boards: AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Boston Skin Science (KP Away), Burt’s Bees, Castle Biosciences, Concerto Biosciences, Dermavant, Dermira, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosciences, Kimberly-Clark, Leo Pharma, Level Ex, Lipidor AB, L’Oréal, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, SkinFix, Theraplex, Unilever, Verrica, Yobee Care
Research: AbbVie, AOBiome, Regeneron/Sanofi Genzyme
Patent Holder: Theraplex AIM (patent pending)
Stock Options: Altus Labs, Boston Skin Science (KP Away), Concerto Biosciences, LearnSkin, Micreos, Yobee Care

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest